Angiotensin Converting Enzymes (ACE) Inhibitors Market Overview, Analysis, Growth Opportunities and Forecast to 2026 Appraised By Global Players Pfizer, Inc., AstraZeneca, Novartis AG, Daiichi Sankyo Company, Ltd.

Angiotensin converting enzymes (ACE) inhibitors act by inhibiting the angiotensin converting enzyme (ACE), which is an important component of renin angiotensin system. ACE inhibitors reduce the formation of angiotensin II and facilitate the dilation of blood vessels as well as reduce blood pressure. Angiotensin converting enzyme inhibitors also reduce blood pressure in kidneys. Angiotensin converting enzymes inhibitors (ACE) are effective for the treatment of congestive heart failure, stroke, and high blood pressure. However, overdose of ACE inhibitors may cause kidney failure, allergic reactions, angioedema, and neutropenia.

Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/2746

Market Dynamics

Increasing research and development activities related to study of ACE inhibitors is expected to boost the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, in February 2016, Monia Lorini, in collaboration with Istituto Di Ricerche Farmacologiche Mario Negri initiated clinical phase II study of ACE inhibitors (Lisinopril) for the treatment of extracapillary glomerulonephritis. This study is for evaluating drug safety and efficacy on the patients. It is expected to complete in December 2019.

Furthermore, in June 2014, Cardiology Research UBC initiated clinical trial phase IV to study the effects of statin including Rosuvastatin and Ramipril - angiotensin converting enzymes inhibitors such as Ramipril on coronary flow reserve and microcirculatory resistance in patients with coronary artery dissection. This study is expected to complete in June 2021.

Overdose of angiotensin converting enzyme (ACE) inhibitors is a major factor restraining growth of the ACE inhibitors market. Overdose of ACE inhibitors may lead to various side effects such as dry cough, hyperkalemia (increased blood potassium level), dizziness, headache, and fatigue. Overdose of ACE inhibitors may also cause cancer. For instance, in October 2018, according to Medical Press (medical center in Melbourne, Australia), angiotensin converting enzymes (ACE) inhibitors are used for the treatment of high blood pressure. However, overdose of ACE inhibitors can increases the risk of lung cancer in patients. These drugs are responsible for the excessive production of bradykinin in the lungs. Excessive bradykinin is the main cause of lung cancer.

Key players covered as a part of this study include, Pfizer, Inc., AstraZeneca, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company and Bayer AG.

Detailed Segmentation:

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs:

Benazepril
Perindopril
Trandolapril
Captopril
Enalaopril
Lisinopril
Ramipril
Others

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Application:

Hypertension
Coronary artery disease
Heart failure
Chronic kidney disease
Scleroderma
Migraine

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Angiotensin Converting Enzymes (ACE) Inhibitors market, By Region:

North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Increasing Prevalence Of Hypertension Is Expected To Drive Growth Of The Angiotensin Converting Enzymes (Ace) Inhibitors Market

Increasing prevalence of hypertension is one of the major drivers for the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, according to World Health Organization’s (WHO) report, in 2018, around 207 million people including 112 million men and 95 million women suffer from hypertension, annually in India.

Moreover, increasing number of research and development activities for improvement of cardiovascular functions during pregnancy is expected to propel the angiotensin converting enzyme (ACE) inhibitors market growth. For instance, in September 2018, Manchester University NHS Foundation Trust initiated clinical Phase II study of Enalapril Maleate for the pre-eclampsia condition. This study is for evaluating drug safety and efficacy on the patients. Pre-eclampsia condition is a pregnancy complication characterized by high blood pressure. It has various signs and symptoms including proteinuria, upper abdominal pain, and shortness of breath.

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2746

Angiotensin Converting Enzymes (ACE) Inhibitors Market - Regional Analysis

Regional segmentation of the global angiotensin converting enzymes (ACE) inhibitors market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America angiotensin converting enzymes (ACE) inhibitors market is expected to account for the largest market share, owing increasing approval activities by the U.S. Food and Drug Administration (FDA). For instance, in August 2016, Silvergate Pharmaceutical Inc. received the U.S. FDA approval for its Qbrelis, containing Lisinopril, an oral solution 1 mg/ml. This drug is indicated for the treatment of hypertension in adult and in children.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.